CRISPR Therapeutics AG
CRSP
$56.25
-$0.43-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 47.67% | 72.53% | 71.63% | -82.26% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.67% | 72.53% | 71.63% | -82.26% | -- |
| Cost of Revenue | 180.03% | -13.04% | 5.57% | -28.65% | -79.76% |
| Gross Profit | -183.57% | 13.37% | -5.30% | -153.99% | 80.28% |
| SG&A Expenses | -2.80% | -2.90% | 7.48% | 9.98% | -4.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.06% | -11.74% | 5.81% | -23.81% | -16.37% |
| Operating Income | -19.91% | 12.02% | -5.57% | -192.82% | 16.83% |
| Income Before Tax | -24.40% | -65.65% | -16.42% | -140.87% | 23.87% |
| Income Tax Expenses | -29.34% | 0.39% | 53.18% | 200.43% | 112.62% |
| Earnings from Continuing Operations | -23.85% | -64.98% | -16.64% | -141.76% | 23.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.85% | -64.98% | -16.64% | -141.76% | 23.37% |
| EBIT | -19.91% | 12.02% | -5.57% | -192.82% | 16.83% |
| EBITDA | -21.10% | 12.29% | -5.84% | -180.21% | 17.33% |
| EPS Basic | -15.62% | -60.91% | -11.02% | -138.94% | 28.60% |
| Normalized Basic EPS | -16.13% | 13.48% | -10.81% | -138.10% | 29.07% |
| EPS Diluted | -15.84% | -61.07% | -10.66% | -139.88% | 28.48% |
| Normalized Diluted EPS | -16.13% | 13.48% | -10.81% | -138.89% | 29.07% |
| Average Basic Shares Outstanding | 7.12% | 2.53% | 5.07% | 7.25% | 7.33% |
| Average Diluted Shares Outstanding | 7.12% | 2.53% | 5.07% | 5.09% | 7.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |